159 related articles for article (PubMed ID: 20885012)
21. Methotrexate and leflunomide: biochemical basis for combination therapy in the treatment of rheumatoid arthritis.
Kremer JM
Semin Arthritis Rheum; 1999 Aug; 29(1):14-26. PubMed ID: 10468411
[TBL] [Abstract][Full Text] [Related]
22. Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases.
Herrmann ML; Schleyerbach R; Kirschbaum BJ
Immunopharmacology; 2000 May; 47(2-3):273-89. PubMed ID: 10878294
[TBL] [Abstract][Full Text] [Related]
23. [Alopecia areata secondary to the use of leflunomide in patients with rheumatoid arthritis: a case report and literature review].
Molina Molina MI; Pinochet Paiva CM; Quezada Morales JI
Medwave; 2015 Dec; 15(11):e6350. PubMed ID: 26819061
[TBL] [Abstract][Full Text] [Related]
24. The changes in serum chemokines following leflunomide therapy in patients with rheumatoid arthritis.
Klimiuk PA; Kita J; Chwiecko J; Sierakowski S
Clin Rheumatol; 2009 Jan; 28(1):17-21. PubMed ID: 18663553
[TBL] [Abstract][Full Text] [Related]
25. Disease modification in rheumatoid arthritis with leflunomide.
Emery P
Scand J Rheumatol Suppl; 1999; 112():9-14. PubMed ID: 10668522
[TBL] [Abstract][Full Text] [Related]
26. Changes in focal adhesion kinase expression in rats with collagen-induced arthritis and efficacy of intervention with disease modifying anti-rheumatic drugs alone or in combination.
Gao HY; Luo J; Li XF; Lv Q; Wen HY; Song QZ; Zhao WP; Zhao XC; Zhang TT; Zhang SY; Zhi JM
Int J Clin Exp Pathol; 2015; 8(12):15573-81. PubMed ID: 26884826
[TBL] [Abstract][Full Text] [Related]
27. Safety and retention of combination triple disease-modifying anti-rheumatic drugs in new-onset rheumatoid arthritis.
Cummins L; Katikireddi VS; Shankaranarayana S; Su KY; Duggan E; Videm V; Pahau H; Thomas R
Intern Med J; 2015 Dec; 45(12):1266-73. PubMed ID: 26384029
[TBL] [Abstract][Full Text] [Related]
28. Long-term efficacy of leflunomide on disease activity and inhibition of joint damage: retrospective comparison with methotrexate for Japanese rheumatoid arthritis patients.
Katayama K; Matsuno T
Mod Rheumatol; 2009; 19(5):513-21. PubMed ID: 19603251
[TBL] [Abstract][Full Text] [Related]
29. [Acute interstitial pneumonia in patient with rheumatoid arthritis treated with leflunomide].
Siemion-Szcześniak I; Bartoszuk I; Bartosiewicz M; Jakubowska L; Wesołowski S; Kuś J
Pneumonol Alergol Pol; 2014; 82(6):568-75. PubMed ID: 25339568
[TBL] [Abstract][Full Text] [Related]
30. Risk of hepatotoxicity with add-on leflunomide in rheumatoid arthritis patients.
Gupta R; Bhatia J; Gupta SK
Arzneimittelforschung; 2011; 61(5):312-6. PubMed ID: 21755815
[TBL] [Abstract][Full Text] [Related]
31. The efficacy of leflunomide monotherapy in rheumatoid arthritis: towards the goals of disease modifying antirheumatic drug therapy.
Smolen JS; Emery P; Kalden JR; Van Riel PL; Dougados M; Strand CV; Breedveld FC
J Rheumatol Suppl; 2004 Jun; 71():13-20. PubMed ID: 15170903
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of leflunomide in DMARD-naive patients with early rheumatoid arthritis: comparison of a loading and a fixed-dose regimen.
Cutolo M; Bolosiu H; Perdriset G;
Rheumatology (Oxford); 2013 Jun; 52(6):1132-40. PubMed ID: 23401601
[TBL] [Abstract][Full Text] [Related]
33. [Leflunomide as a second choice treatment in patients with rheumatoid arthritis].
Raczkiewicz-Papierska A; Dudek A; Bachta A; Tłustochowicz M; Zawadyl B; Sułek M
Pol Merkur Lekarski; 2007 Jun; 22(132):547-50. PubMed ID: 17874627
[TBL] [Abstract][Full Text] [Related]
34. Involvement of breast cancer resistance protein expression on rheumatoid arthritis synovial tissue macrophages in resistance to methotrexate and leflunomide.
van der Heijden JW; Oerlemans R; Tak PP; Assaraf YG; Kraan MC; Scheffer GL; van der Laken CJ; Lems WF; Scheper RJ; Dijkmans BA; Jansen G
Arthritis Rheum; 2009 Mar; 60(3):669-77. PubMed ID: 19248091
[TBL] [Abstract][Full Text] [Related]
35. [Experience in long-term therapy of active rheumatoid arthritis with leflunomide].
Chichasova NV; Igolkina EV; Brodetskaia KA; Imametdinova GR
Ter Arkh; 2005; 77(5):33-8. PubMed ID: 15989000
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of leflunomide in active rheumatoid arthritis.
Smolen JS; Emery P
Rheumatology (Oxford); 2000 Jun; 39 Suppl 1():48-56. PubMed ID: 11001380
[TBL] [Abstract][Full Text] [Related]
37. Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD.
Cannon GW; Holden WL; Juhaeri J; Dai W; Scarazzini L; Stang P
J Rheumatol; 2004 Oct; 31(10):1906-11. PubMed ID: 15468352
[TBL] [Abstract][Full Text] [Related]
38. Leflunomide: a novel DMARD for the treatment of rheumatoid arthritis.
Alldred A; Emery P
Expert Opin Pharmacother; 2001 Jan; 2(1):125-37. PubMed ID: 11336574
[TBL] [Abstract][Full Text] [Related]
39. Combination of cyclosporine and leflunomide versus single therapy in severe rheumatoid arthritis.
Karanikolas G; Charalambopoulos D; Andrianakos A; Antoniades C; Katsilambros N
J Rheumatol; 2006 Mar; 33(3):486-9. PubMed ID: 16511917
[TBL] [Abstract][Full Text] [Related]
40. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year followup study.
Kalden JR; Schattenkirchner M; Sörensen H; Emery P; Deighton C; Rozman B; Breedveld F
Arthritis Rheum; 2003 Jun; 48(6):1513-20. PubMed ID: 12794818
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
